Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Current Ocaliva Liver Safety FDA Evaluation Started Back in May 2020

October 15, 2020 By Law Offices of Thomas J. Lamb, P.A.

In October 2020 we first learned about a “new” drug safety issue for Ocaliva — although it apparently has been on the FDA’s radar since at least May 2020. It seems a possible Ocaliva liver-related side effects risk has attracted scrutiny, and there is an Ocaliva liver safety FDA evaluation underway.

It was this October 9, 2020, Endpoints News article, “In another blow to Intercept, the FDA is investigating Ocaliva for potential risk of liver disorder”, which brought to light an Ocaliva liver safety FDA evaluation. It was further reported in this article that a spokesman for Intercept, the pharmaceutical company responsible for Ocaliva, said he anticipates the current FDA safety investigation about Ocaliva liver-related side effects would take about 12 months.

Ocaliva (obeticholic acid) was approved by the FDA in 2016 for the treatment of a rare chronic liver disease, primary biliary cholangitis (PBC). Specifically, Ocaliva is FDA-approved for use in combination with ursodeoxycholic acid (UDCA) in adult PBC patients with an inadequate response to UDCA, or as monotherapy in adult PBC patients unable to tolerate UDCA.

Back in 2017 and 2018, the FDA warned that Ocaliva was being incorrectly dosed daily instead of weekly in patients with PBC, and thereby increasing the risk of serious liver injury. For the details of this earlier drug safety issue for Ocaliva, see “FDA adds Boxed Warning to highlight correct dosing of Ocaliva (obeticholic acid) for patients with a rare chronic liver disease”.

Given that the current Ocaliva liver safety FDA evaluation began about five months ago, we can look for the results of this FDA in or about May 2021.

Of course, we will continue to monitor the safety of Ocaliva and this Ocaliva liver-related side effects FDA investigation going forward.

[View article at original source]

Ocaliva

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: drug-induced liver injury, liver damage, liver failure, liver injury, Ocaliva

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.